@article{1066e8c507ba414d87d4baba3f8a092a,
title = "Definition and treatment of arrhythmogenic cardiomyopathy: an updated expert panel report",
abstract = "It is 35 years since the first description of arrhythmogenic right ventricular cardiomyopathy (ARVC) and more than 20 years since the first reports establishing desmosomal gene mutations as a major cause of the disease. Early advances in the understanding of the clinical, pathological and genetic architecture of ARVC resulted in consensus diagnostic criteria, which proved to be sensitive but not entirely specific for the disease. In more recent years, clinical and genetic data from families and the recognition of a much broader spectrum of structural disorders affecting both ventricles and associated with a propensity to ventricular arrhythmia have raised many questions about pathogenesis, disease terminology and clinical management. In this paper, we present the conclusions of an expert round table that aimed to summarise the current state of the art in arrhythmogenic cardiomyopathies and to define future research priorities.",
keywords = "Arrhythmogenic cardiomyopathy, Arrhythmogenic right ventricular cardiomyopathy, Ventricular arrhythmias",
author = "Elliott, {Perry M.} and Aris Anastasakis and Angeliki Asimaki and Cristina Basso and Barbara Bauce and Brooke, {Matthew A.} and Hugh Calkins and Domenico Corrado and Firat Duru and Green, {Kathleen J.} and Judge, {Daniel P.} and David Kelsell and Lambiase, {Pier D.} and McKenna, {William J.} and Kalliopi Pilichou and Alexandros Protonotarios and Saffitz, {Jeffrey E.} and Petros Syrris and Hari Tandri and {Te Riele}, Anneline and Gaetano Thiene and Adalena Tsatsopoulou and {van Tintelen}, {J. Peter}",
note = "Funding Information: This project was an independent initiative supported by the Fondazione Internazionale Menarini, which had no part in designing or approving the agenda. St. Bartholomew's Hospital, the Amsterdam UMC and the Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua-Azienda Ospedaliera are members of ERN GUARD-HEART (European Reference Network for Rare and Complex Diseases of the Heart; http://guardheart.ern-net.eu), which endorsed the meeting. Conflict of interest: H.C. reports grants and personal fees from Boston Scientifiic, and personal fees from Medtronic, St Jude Medical, during the conduct of the study. D.P.J. reports grants from Menarini Foundation, during the conduct of the study; personal fees from Alnylam, GlaxoSmithKline, Pfizer, outside the submitted work. H.T. reports personal fees from Abbott, Cooltech, outside the submitted work. All other authors have nothing to disclose. Funding Information: This project was an independent initiative supported by the Fon-dazione Internazionale Menarini, which had no part in designing or approving the agenda. St. Bartholomew{\textquoteright}s Hospital, the Amsterdam UMC and the Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padua-Azienda Ospedaliera are members of ERN GUARD-HEART (European Reference Network for Rare and Complex Diseases of the Heart; http://guardheart.ern-net.eu), which endorsed the meeting. Conflict of interest: H.C. reports grants and personal fees from Boston Scientifiic, and personal fees from Medtronic, St Jude Medical, during the conduct of the study. D.P.J. reports grants from Menarini Foundation, during the conduct of the study; personal fees from Alnylam, GlaxoSmithKline, Pfizer, outside the submitted work. H.T. reports personal fees from Abbott, Cooltech, outside the submitted work. All other authors have nothing to disclose. Publisher Copyright: {\textcopyright} 2019 The Authors. European Journal of Heart Failure {\textcopyright} 2019 European Society of Cardiology",
year = "2019",
month = aug,
doi = "10.1002/ejhf.1534",
language = "English",
volume = "21",
pages = "955--964",
journal = "European Journal of Heart Failure",
issn = "1388-9842",
publisher = "Oxford University Press",
number = "8",
}